Get the Stockscreener App
16.12
5.18%
-0.88
After Hours:
16.58
0.46
+2.85%
Cartesian Therapeutics Inc stock is traded at $16.12, with a volume of 76,850.
It is down -5.18% in the last 24 hours and up +15.47% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
See More
Previous Close:
$17.00
Open:
$17
24h Volume:
76,850
Relative Volume:
0.55
Market Cap:
$346.69M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-51.37M
1W Performance:
+8.41%
1M Performance:
+15.47%
6M Performance:
-17.33%
1Y Performance:
+0.00%
1-Day Range:
$15.55
$17.06
1-Week Range:
$14.00
$17.50
52-Week Range:
$11.66
$42.60
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
617-923-1400
Address
704 QUINCE ORCHARD RD, GAITHERSBURG
Cartesian Therapeutics Inc Stock (RNAC) Latest News
1,725 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Acquired by Point72 DIFC Ltd - Defense World
Rhumbline Advisers Sells 121,396 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Mizuho affirms Outperform on Cartesian Therapeutics stock, highlights Descartes-08’s competitive edge - Investing.com Canada
Logos Global Management LP Invests $2.43 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Australia
Logos Global Management LP Buys Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Bank of New York Mellon Corp Has $538,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Canada
Cartesian Therapeutics gets shareholder nod for stock issuance - Investing.com
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com UK
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics Receives FDA Rare Pediatric Disease - GlobeNewswire
FDA grants rare pediatric status for Cartesian’s Descartes-08 - The Pharma Letter
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment - MarketWatch
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis - Yahoo Finance
Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma - CGTLive™
Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewswire
Cartesian Therapeutics Announces New Employment Inducement Grant - StockTitan
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics shares maintain Buy rating as new trial kicks off - Investing.com Canada
Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com India
Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com Canada
Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com Australia
Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com
Cartesian advances new mRNA therapy into Phase 1 trial By Investing.com - Investing.com UK
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - GlobeNewswire
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - StockTitan
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - Yahoo Finance
Around the Helix: Cell and Gene Therapy Company Updates – August 28, 2024 - CGTLive™
By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights - GlobeNewswire Inc.
JW Therapeutics’ Relma-Cell Approved in China for R/R Mantle Cell Lymphoma - CGTLive™
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
New Spinoza on CAR Ts: Cartesian, others pursue autoimmune - BioWorld Online
RNAC’s latest rating updates from top analysts. - Knox Daily
Hall Laurie J Trustee Has $48,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
6,315,113 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Vanguard Group Inc. - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Timothy A. Springer Buys 8,016 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Cartesian therapeutics director Barabe buys $95,250 in stock By Investing.com - Investing.com Australia
Timothy Springer buys $101,967 in Cartesian Therapeutics stock - Investing.com India
Cartesian therapeutics director Barabe buys $95,250 in stock - Investing.com India
Cartesian therapeutics director Barabe buys $95,250 in stock - Investing.com
Cartesian therapeutics director Barabe buys $95,250 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):